Schulze Diabetes Institute, University of Minnesota, Minneapolis, MN 55455, USA.
J Am Coll Surg. 2012 Apr;214(4):409-24; discussion 424-6. doi: 10.1016/j.jamcollsurg.2011.12.040. Epub 2012 Mar 6.
Total pancreatectomy (TP) with intraportal islet autotransplantation (IAT) can relieve pain and preserve β-cell mass in patients with chronic pancreatitis (CP) when other therapies fail. We report on a >30-year single-center series.
Four hundred and nine patients (including 53 children, 5 to 18 years) with CP underwent TP-IAT from February 1977 to September 2011 (etiology: idiopathic, 41%; Sphincter of Oddi dysfunction/biliary, 9%; genetic, 14%; divisum, 17%; alcohol, 7%; and other, 12%; mean age was 35.3 years, 74% were female; 21% has earlier operations, including 9% Puestow procedure, 6% Whipple, 7% distal pancreatectomy, and 2% other). Islet function was classified as insulin independent for those on no insulin; partial, if known C-peptide positive or euglycemic on once-daily insulin; and insulin dependent if on standard basal-bolus diabetic regimen. A 36-item Short Form (SF-36) survey for quality of life was completed by patients before and in serial follow-up since 2007, with an integrated survey that was added in 2008.
Actuarial patient survival post TP-IAT was 96% in adults and 98% in children (1 year) and 89% and 98% (5 years). Complications requiring relaparotomy occurred in 15.9% and bleeding (9.5%) was the most common complication. IAT function was achieved in 90% (C-peptide >0.6 ng/mL). At 3 years, 30% were insulin independent (25% in adults, 55% in children) and 33% had partial function. Mean hemoglobin A1c was <7.0% in 82%. Earlier pancreas surgery lowered islet yield (2,712 vs 4,077/kg; p = 0.003). Islet yield (<2,500/kg [36%]; 2,501 to 5,000/kg [39%]; >5,000/kg [24%]) correlated with degree of function with insulin-independent rates at 3 years of 12%, 22%, and 72%, and rates of partial function 33%, 62%, and 24%. All patients had pain before TP-IAT and nearly all were on daily narcotics. After TP-IAT, 85% had pain improvement. By 2 years, 59% had ceased narcotics. All children were on narcotics before, 39% at follow-up; pain improved in 94%; and 67% became pain-free. In the SF-36 survey, there was significant improvement from baseline in all dimensions, including the Physical and Mental Component Summaries (p < 0.01), whether on narcotics or not.
TP can ameliorate pain and improve quality of life in otherwise refractory CP patients, even if narcotic withdrawal is delayed or incomplete because of earlier long-term use. IAT preserves meaningful islet function in most patients and substantial islet function in more than two thirds of patients, with insulin independence occurring in one quarter of adults and half the children.
全胰切除术(TP)联合门静脉胰岛自体移植(IAT)可以在其他治疗方法失败时缓解慢性胰腺炎(CP)患者的疼痛并保留β细胞量。我们报告了一个超过 30 年的单中心系列研究。
从 1977 年 2 月至 2011 年 9 月,共有 409 例(包括 53 例儿童,年龄 5 至 18 岁)接受了 TP-IAT 手术,病因包括特发性(41%)、Oddi 括约肌功能障碍/胆道(9%)、遗传(14%)、分裂(17%)、酒精(7%)和其他(12%);平均年龄为 35.3 岁,74%为女性;21%之前有过手术,包括 9%的 Puestow 手术、6%的 Whipple 手术、7%的胰尾部切除术和 2%的其他手术)。胰岛功能被分为胰岛素非依赖性(无需胰岛素)、部分依赖性(已知 C 肽阳性或每日一次胰岛素治疗时血糖正常)和胰岛素依赖性(需要标准的基础-餐时胰岛素方案)。自 2007 年以来,患者在接受手术前后通过 36 项简短健康调查问卷(SF-36)完成了生活质量的综合调查,2008 年增加了一项综合调查。
TP-IAT 术后成人患者的生存率为 96%,儿童患者为 98%(1 年)和 89%和 98%(5 年)。需要再次剖腹手术的并发症发生率为 15.9%,出血(9.5%)是最常见的并发症。90%的患者 IAT 功能达到(C 肽>0.6ng/mL)。3 年后,30%的患者无需胰岛素(25%的成年患者,55%的儿童患者),33%的患者有部分功能。82%的患者平均血红蛋白 A1c<7.0%。早期胰腺手术降低了胰岛产量(2712 比 4077/kg;p=0.003)。胰岛产量(<2500/kg[36%];2501-5000/kg[39%];>5000/kg[24%])与功能程度相关,3 年后胰岛素非依赖性的比例分别为 12%、22%和 72%,部分功能的比例分别为 33%、62%和 24%。所有患者在接受 TP-IAT 手术前都有疼痛,且几乎都在服用止痛药。TP-IAT 后,85%的患者疼痛得到改善。2 年后,59%的患者停止服用止痛药。所有儿童患者术前都需要服用止痛药,39%的患者在随访时仍需要服用止痛药;疼痛改善的比例为 94%;67%的患者不再疼痛。在 SF-36 调查中,无论是否服用止痛药,所有维度的评分都有显著改善,包括生理和心理综合评分(p<0.01)。
TP 可以缓解难治性 CP 患者的疼痛,改善生活质量,即使因长期使用而导致药物戒断延迟或不完全。IAT 可保留大多数患者有意义的胰岛功能,超过三分之二的患者有大量的胰岛功能,成年患者中有四分之一和一半的儿童患者无需胰岛素。